Effect of orlistat on plasma lipids and body weight: A systematic review and meta‐analysis of 33 randomized controlled trials

[1]  A. Sahebkar,et al.  The effects of a nutraceutical combination on plasma lipids and glucose: A systematic review and meta-analysis of randomized controlled trials. , 2016, Pharmacological research.

[2]  Ž. Reiner.  Are Elevated Serum Triglycerides Really a Risk Factor for Coronary Artery Disease? , 2015, Cardiology.

[3]  G. Lip,et al.  Analysis of vitamin D levels in patients with and without statin-associated myalgia - a systematic review and meta-analysis of 7 studies with 2420 patients. , 2015, International journal of cardiology.

[4]  A. Sahebkar,et al.  Recent advances in pharmacotherapy for hypertriglyceridemia. , 2014, Progress in lipid research.

[5]  Anette Varbo,et al.  Triglycerides and cardiovascular disease , 2014, The Lancet.

[6]  Jiming Liu,et al.  Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range , 2014, BMC Medical Research Methodology.

[7]  G. Watts,et al.  New peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease , 2014, Expert opinion on pharmacotherapy.

[8]  Ž. Reiner.  Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update. , 2013, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[9]  E. Mannarino,et al.  A silent mutation of Niemann-Pick C1-like 1 and apolipoprotein E4 modulate cholesterol absorption in primary hyperlipidemias. , 2013, Journal of clinical lipidology.

[10]  J. Sowers,et al.  Obesity and the Cardiorenal Metabolic Syndrome: Therapeutic Modalities and Their Efficacy in Improving Cardiovascular and Renal Risk Factors , 2012, Cardiorenal Medicine.

[11]  Shah Ebrahim,et al.  European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (Version 2012) , 2012, International Journal of Behavioral Medicine.

[12]  Jin-fang Xu,et al.  Effect of Anti-Obesity Drug on Cardiovascular Risk Factors: A Systematic Review and Meta-Analysis of Randomized Controlled Trials , 2012, PloS one.

[13]  M. Stampfer,et al.  Adherence to weight loss medications; post-marketing study from HMO pharmacy data of one million individuals. , 2011, Diabetes research and clinical practice.

[14]  J. Després,et al.  Treatment of lipid disorders in obesity , 2011, Expert review of cardiovascular therapy.

[15]  E. Mannarino,et al.  Cardiovascular risk factors and recommended lipid goals attainment among patients referred in a tertiary care lipid clinic. , 2011, European journal of internal medicine.

[16]  M. Taskinen,et al.  ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). , 2011, Atherosclerosis.

[17]  P. Kolh,et al.  ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). , 2011, European heart journal.

[18]  J. Borén,et al.  Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management , 2011, European heart journal.

[19]  J. Borén,et al.  Lipoprotein(a) as a cardiovascular risk factor: current status , 2010, European heart journal.

[20]  S. Grambow,et al.  A randomized trial of a low-carbohydrate diet vs orlistat plus a low-fat diet for weight loss. , 2010, Archives of internal medicine.

[21]  P. Silva,et al.  Estudo Comparativo, Aleatorizado, em Dupla Ocultação, de Orlistat Versus Placebo, de Eficácia e Segurança, em Doentes Obesos com Hipercolesterolemia Ligeira a Moderada , 2009 .

[22]  S. Rössner,et al.  Discontinuation due to adverse events in randomized trials of orlistat, sibutramine and rimonabant: a meta‐analysis , 2009, Obesity reviews : an official journal of the International Association for the Study of Obesity.

[23]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement , 2009, BMJ : British Medical Journal.

[24]  M. Elisaf,et al.  The effects of ezetimibe and orlistat, alone or in combination, on high-density lipoprotein (HDL) subclasses and HDL-associated enzyme activities in overweight and obese patients with hyperlipidaemia , 2008, Expert opinion on pharmacotherapy.

[25]  F. Sacks,et al.  The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patients , 2008, Diabetes & vascular disease research.

[26]  Steven Hawken,et al.  Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study , 2008, The Lancet.

[27]  M. Kostapanos,et al.  The effects of orlistat and fenofibrate, alone or in combination, on high‐density lipoprotein subfractions and pre‐beta1‐HDL levels in obese patients with metabolic syndrome , 2008, Diabetes, obesity & metabolism.

[28]  J. Fanchiang,et al.  Comparison of the effects of sibutramine and orlistat on obese, poorly-controlled type 2 diabetic patients. , 2007, Chang Gung medical journal.

[29]  M. Etminan,et al.  Long-term persistence with orlistat and sibutramine in a population-based cohort , 2007, International Journal of Obesity.

[30]  G. Winkler,et al.  Orlistat increases serum paraoxonase activity in obese patients. , 2007, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[31]  S. Toubro,et al.  Effect of Orlistat on Weight Regain and Cardiovascular Risk Factors Following a Very-Low-Energy Diet in Abdominally Obese Patients , 2007, Diabetes Care.

[32]  M. Boldrin,et al.  Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial. , 2005, JAMA.

[33]  B. Swinburn,et al.  Effect of orlistat on cardiovascular disease risk in obese adults , 2005, Diabetes, obesity & metabolism.

[34]  S. Atkin,et al.  Orlistat is as beneficial as metformin in the treatment of polycystic ovarian syndrome. , 2005, The Journal of clinical endocrinology and metabolism.

[35]  R. Fogari,et al.  Efficacy and safety comparative evaluation of orlistat and sibutramine treatment in hypertensive obese patients , 2005, Diabetes, obesity & metabolism.

[36]  H. Gin,et al.  Effects of orlistat on obesity‐related diseases – a six‐month randomized trial , 2004, Diabetes, obesity & metabolism.

[37]  V. Schusdziarra,et al.  Cholesterol lowering effect of dietary weight loss and orlistat treatment – efficacy and limitations , 2004, Alimentary pharmacology & therapeutics.

[38]  Z. Latif,et al.  Orlistat as an adjunct therapy in type 2 obese diabetic patients treated with sulphonylurea: a Bangladesh experience. , 2004, Bangladesh Medical Research Council bulletin.

[39]  J. Foreyt,et al.  Weight loss in obese Mexican Americans treated for 1-year with orlistat and lifestyle modification , 2003, International Journal of Obesity.

[40]  B. Howard,et al.  Obesity and dyslipidemia. , 2003, Endocrinology and metabolism clinics of North America.

[41]  E. Muxfeldt,et al.  Orlistat in hypertensive overweight/obese patients: results of a randomized clinical trial , 2003, Journal of hypertension.

[42]  M. Fraser,et al.  Effect of Orlistat in obese patients with heart failure: a pilot study. , 2003, Congestive heart failure.

[43]  A. Rissanen,et al.  Lowering of LDL cholesterol rather than moderate weight loss improves endothelium-dependent vasodilatation in obese women with previous gestational diabetes. , 2003, Diabetes care.

[44]  A. Halpern,et al.  Latin‐American trial of orlistat for weight loss and improvement in glycaemic profile in obese diabetic patients , 2003, Diabetes, obesity & metabolism.

[45]  G. Reaven,et al.  Effect of orlistat added to diet (30% of calories from fat) on plasma lipids, glucose, and insulin in obese patients with hypercholesterolemia. , 2003, The American journal of cardiology.

[46]  R. Fogari,et al.  Randomized, double-blind, placebo-controlled comparison of the action of orlistat, fluvastatin, or both an anthropometric measurements, blood pressure, and lipid profile in obese patients with hypercholesterolemia prescribed a standardized diet. , 2003, Clinical therapeutics.

[47]  G. Bakris,et al.  Orlistat improves blood pressure control in obese subjects with treated but inadequately controlled hypertension , 2002, Journal of hypertension.

[48]  L. Aronne,et al.  Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin. , 2002, Diabetes care.

[49]  F Xavier Pi-Sunyer,et al.  Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: A 1-year randomized controlled trial. , 2002, Diabetes care.

[50]  E. Muls,et al.  The effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled, multicentre study , 2001, International Journal of Obesity.

[51]  S. Klein,et al.  Orlistat inhibits dietary cholesterol absorption. , 2001, Obesity research.

[52]  G. Reaven,et al.  Effect of orlistat-assisted weight loss in decreasing coronary heart disease risk in patients with syndrome X. , 2001, The American journal of cardiology.

[53]  Alex J. Sutton,et al.  Methods for Meta-Analysis in Medical Research , 2000 .

[54]  F. Lindgärde.  The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: The Swedish Multimorbidity Study , 2000, Journal of internal medicine.

[55]  S Duval,et al.  Trim and Fill: A Simple Funnel‐Plot–Based Method of Testing and Adjusting for Publication Bias in Meta‐Analysis , 2000, Biometrics.

[56]  G. Williams,et al.  One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor , 2000, International Journal of Obesity.

[57]  K. Fujioka,et al.  Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-y study. , 1999, The American journal of clinical nutrition.

[58]  S. Heymsfield,et al.  Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. , 1999, JAMA.

[59]  Alain Golay,et al.  Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients , 1998, The Lancet.

[60]  P. Kris-Etherton,et al.  Effects of reducing dietary saturated fatty acids on plasma lipids and lipoproteins in healthy subjects: the DELTA Study, protocol 1. , 1998, Arteriosclerosis, thrombosis, and vascular biology.

[61]  J. Zhi,et al.  Retrospective population‐based analysis of the dose‐response (fecal fat excretion) relationship of orlistat in normal and obese volunteers , 1994, Clinical pharmacology and therapeutics.

[62]  A M Dattilo,et al.  Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis. , 1992, The American journal of clinical nutrition.

[63]  P. Hadváry,et al.  Inhibition of pancreatic lipase in vitro by the covalent inhibitor tetrahydrolipstatin. , 1988, The Biochemical journal.

[64]  W. Castelli,et al.  Cholesterol and lipids in the risk of coronary artery disease--the Framingham Heart Study. , 1988, The Canadian journal of cardiology.

[65]  M C Hjortland,et al.  High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. , 1977, The American journal of medicine.

[66]  P. M. da Silva,et al.  A randomized double-blind study comparing the efficacy and safety of orlistat versus placebo in obese patients with mild to moderate hypercholesterolemia. , 2009, Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology.

[67]  C. Hsieh,et al.  Orlistat for obesity: benefits beyond weight loss. , 2005, Diabetes research and clinical practice.

[68]  S. Tonstad,et al.  The effect of the gastrointestinal lipase inhibitor, orlistat, on serum lipids and lipoproteins in patients with primary hyperlipidaemia , 2004, European Journal of Clinical Pharmacology.

[69]  L. Sjöström,et al.  XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. , 2004, Diabetes care.

[70]  Shah Ebrahim,et al.  European guidelines on cardiovascular disease prevention in clinical practice , 2004 .

[71]  S. Rössner,et al.  Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group. , 2000, Obesity research.